PEDIATRIC LATE OUTCOMES (AIDS CLINICAL TRIAL GROUP # 219)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives are: 1. To describe late outcomes over time in growth, neurologic and neuropsychologic function, organ system toxicity, development of cancer, and immunologic and virologic parameters in human immunodeficiency virus (HIV) infected infants, children, and adolescents, currently or previously enrolled in pediatric ACTG protocols, and to evaluate the potential late effects of therapies, including vaccines, received by these children. 2. To determine if infants with indeterminate HIV status who enroll in ACTG neonatal/early infancy protocols involving antiretrovirals, vaccines, or immunotherapy, and uninfected infants born to HIV-infected women who were enrolled in perinatal or antiretroviral/immunomodulator therapy ACTG protocols while pregnant demonstrate any short or long term clinical, neurologic, neuropsychologic, or organ system late effects of antiretroviral therapy received in utero and/or in the newborn period. This will include evaluation of late effects (either positive or negative) of vaccine therapies. 3. To follow overall survival, morbidity, and quality of life in successive cohorts of HIV infected infants, children, and adolescents enrolled in ACTG protocols.